Veronica Wu, founder of First Bight Ventures, joins the Houston Innovators Podcast to outline Houston's opportunities in synthetic biology and biomanufacturing. Photo courtesy

Houston has all the ingredients to be a successful synthetic biology hub, says Veronica Wu. She believes so strongly in this that she relocated to Houston from Silicon Valley just over a year ago to start a venture capital firm dedicated to the field. Since then, she's doubled down on her passion for Houston leading in biotech — especially when it comes to one uniquely Houston opportunity: biomanufacturing.

While Houston's health care innovation scene is actively deploying synthetic biology applications, Wu points to Houston-based Solugen, a plant-based chemical producer, as an example of what Houston has to offer at-scale industrial biomanufacturing. Houston has the workforce and the physical space available for more of these types of biomanufacturing plants, which have a huge potential to move the needle on reducing carbon emissions.

"This is really fundamental technology that's going to change the paradigm and whole dialogue of how we are making a significant impact in reducing a carbon footprint and improving sustainability," says Wu, founder and managing partner of First Bight Ventures, on the Houston Innovators Podcast.

Several aspects — government funding, corporate interest, advances in technology — have converged to make it an ideal time for synthetic biology innovators and investors, Wu explains on the show, and she has an idea of what Houston needs to secure its spot as a leader in the space: The BioWell.

First introduced at a Houston Tech Rodeo event at the Texas Medical Center's Innovation Factory, The BioWell is a public-private partnership that aims to provide access to pilot and lab space, mentorship and programming, and more support that biomanufacturing innovators critically need.

"The way we envision The BioWell is it will provide a holistic, curated support for startups to be able to get across the Valley of Death," Wu says, explaining that startups transitioning from research and development into commercialization need extra support. The BioWell will provide that, as well as allow more engagement from corporations, investors, and other players.

Now that her plans for The BioWell have been announced, Wu is looking for those who want to be a part of it.

She shares more about her mission and what's next for First Bight Ventures on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Finding funding is tough and might get you in the mother of all holes — the Valley of Death. Miguel Tovar/University of Houston

7 ways to escape the Valley of Death, according to University of Houston research

Houston Voices

To walk through the valley of death means that death and misery are low points (valleys) in the human experience through which we all must inevitably walk and experience.

Although not as morbid, in the world of startup businesses, the valley of death is still grim. It is a low point in your startup's life where your business suffers and all seems lost. Specifically, it describes how hard it is to cover negative cash flow while you wait for your startup to start generating revenue from actual consumers. Sadly, only 10 percent of startups will survive the valley of death after the first three years, according to a Gompers and Lerner analysis.

"Our startup overcame the valley of death by making believers out of investors. Often, you have ideas that are worthwhile, but you have to find investors who also believe that," says Jason Eriksen, Ph.D., associate professor of pharmacology and chair and co-founder of Alzeca Biosciences.

Alzeca develops advanced imaging technology that helps physicians detect Alzheimer's at a much earlier stage than ever before. Alzeca is one of 28 groundbreaking and innovative startups changing the world at UH's Technology Bridge.

"Initially, our investors rejected us because they were disappointed that we couldn't cure Alzheimer's, and that we could merely stage it. That sent us spiraling into the valley of death. We overcame that by making other investors believers. We made them believe in our technology for detecting the disease early and that it would be life-changing for millions of sufferers," Eriksen says.

Here are another seven ways to dig yourself out of, not just a hole, but the mother of all holes: the valley of death.

1. Gather resources.

Planning your business is a good way to minimize risk. Such preparation involves determining how much money you will need to get to the revenue generation stage, and how much money you will need to cover costs in the likely event you fall into a financial hole. The more resources you've accumulated beforehand, the more padding you'll have if you fall on your face.

2. Don't quit your day job.

Keep your day-to-day job to keep money coming in and your personal finances covered. Use your weeknights and weekends to put in work on your company while you wait to generate revenue. You'll be making money while you wait for money. This way might take longer, but with proper planning, you can ensure that your lights will stay on while your startup struggles to bring in revenue while spiraling in the valley of death.

3. Find funding from friends and family.

"Angel investors and venture capitalists will feel a lot better about investing if they see you already have money at stake," Eriksen says.

That pre-investor money usually comes from friends and family. There is some weight to the idea that you should never mix business with family, but there are exceptions.

You're more likely to secure funding from friends and family if you show them you have a more-than-solid business plan. Your loved ones will want to see figures and metrics that have tracked what your business has done or what it is projected to do. They will also want to see that you are an expert in your business. It would also help to show them a payment plan where you outline when and how you will pay their money back.

Once you have friends and family funding secured, you're a lot more likely to acquire more funding from investors, and the long, hard road out of the valley of death begins.

4. Call for crowdfunding.

One smart way to jet pack out of the valley of death is to launch a crowdfunding campaign. If you know your tech, service, or product is a game changer, crowdfunding will put that to the test. This is where you'll obtain funding from everyday people who like what you have to offer enough to put all their faith in it in the form of dollars and cents.

5. Enter competitions and apply for grants.

Enter as many competitions as you can.

"Because of the government's recent surge in focus on tech-based and energy-based startups, there are now more startup competitions available in major VC (venture capitalist) geographic hotspots like San Francisco, Boston, New York, LA, and San Jose," Eriksen says.

While those cities are the startup hotspots, their activity reflects the current market for startups all over the country. Thankfully, that activity is at an all-time high, so you can rest assured that startup competitions are abundant in your own city, too.

This is your chance to show the world your hoverboard and attain funding you don't have to pay back, all without even relinquishing any equity. These competitions are, get this, competitive, so it would wise to register as early as you can.

6. Consider joint venture.

There might be a company out there that sees your product or services as congruent to their own business. Reach out to them and try to convince them that a joint venture would behoove both companies. This approach is not uncommon, and companies have been known to advance funding early on with the expectation that you'll reimburse them once your revenue starts rolling in.

7. Borrow if need be. 

Somewhere out there is a loan with your name on it. Wallowing in the valley of death can really leave a business owner feeling desperate and alone in the world. So desperate, that is, that they might mess around and apply for a loan. This alternative is the nuclear option. A last resort. It's only a viable approach if you're willing to put your home or other big assets on the line as collateral.

Typically, banks will only approve loans to startups that are cash-flow positive. So maybe this option is best if you've succeeded with a few of the aforementioned approaches so much that they helped your company start generating revenue. Once you've reached that point, that's the prime time to apply for a loan or line of credit.

"The phrase 'valley of death' is appropriate because it is a death sentence for the vast majority of startups," warns Eriksen.

That doesn't mean you go down without a fight.

When Buster Douglas fought Mike Tyson, every fan, expert, and sportswriter counted him out. For the entire fight, they were right. His defeat was inevitable. Then the tenth round happened.

Not only did he not go down without a fight, he won the bout. He beat the champ, and the odds. If you want your best chance at beating the odds, you do everything you can. You fight. Loans, competitions, crowdfunding, joint ventures; whatever it takes.

"The valley of death is only a death sentence if you allow it to be."

------

This article originally appeared on the University of Houston's The Big Idea.

The author, Rene Cantu, is the writer and editor at UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston-born Cemvita makes breakthrough in sustainable fuel production

clean fuels

Houston-based biotech company Cemvita announced that it recently reached a critical milestone in the development of its FermOil product, which can be used to create Sustainable Aviation Fuel (SAF) and other renewable fuels at industrial scale.

The company shared in a news release that it completed a 75,000-liter industrial fermentation run at Belgium's Bio Base Europe Pilot Plant.

The campaign achieved target technical metrics for the production of FermOil, Cemvita’s renewable natural oil (RNO). FermOil is produced from industrial crude glycerin, an industrial byproduct, as opposed to traditional sugar-based feedstocks used in many bio-oil fermentation processes. It's designed to be a drop-in feedstock for creating SAFs.

Cemvita had previously advanced its FermOil production process through multiple scale-up stages before successfully reaching the 75,000-liter demonstration campaign, according to the company.

“This is not just a fermentation milestone,” Moji Karimi, CEO at Cemvita, said in the release. “It is a blueprint for how existing industrial infrastructure can evolve into circular bioeconomy infrastructure. Every biodiesel plant generating crude glycerin is a potential platform for renewable natural oil production.”

The milestone also supports the deployment of Cemvita’s industrial biomanufacturing platform, FermWorks, which integrates with existing energy and industrial infrastructure to turn waste carbon streams into SAFs and other materials. According to the release, Cemvita plans to move forward with commercial deployment discussions with partners in Brazil, Europe and in the UK. Cemvita already has a partnership with the Brazilian sustainable research institution REMA.

“We are proud to support innovative companies like Cemvita in scaling breakthrough industrial biotechnology solutions,” Hendrik Waegeman, head of business operations at Bio Base Europe Pilot Plant, added in the release. “Successfully operating at the 75,000-liter scale using a feedstock such as crude glycerin highlights both the maturity of the technology and the quality of the scale-up execution achieved by the Cemvita team.”

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."

7 Houston neighbors named to U.S. News' best places to live in 2026

Living Well

Several Houston suburbs have been crowned the best places to live in the U.S. for 2026, according to U.S. News & World Report. Sugar Land is the highest-ranked city in the Houston metro, and it ranks as the 10th best place to live in the country.

The annual list of Best Places to Live in the U.S. is designed to help readers make the most informed decisions when choosing where to settle down, using data from sources such as the U.S. Census Bureau, Department of Commerce, the Federal Reserve and the Bureau for Economic Analysis, as well as state and local sources.

For the 2026-2027 rankings, U.S. News featured 250 U.S. cities and ranked them across four livability indexes — quality of life, value, desirability, and job market — weighted by importance based on survey results of approximately 500 Americans. The rankings were also broken down state-by-state, as well as the best big, medium, and small cities overall.

Sugar Land is the No. 4 best places to live in Texas, and it soared into the No. 10 spot overall in the nation after ranking 16th last year. Sugar Land also ranks as the fourth-best mid-sized city to live in America for 2026-2027.

According to U.S. News, Sugar Land's median household income is far higher than the national average. Residents make $140,511 per year, while the average American household income is only $83,181.

Additionally, the $431,815 median home value in Sugar Land is also far greater than the $359,870 national average.

After ranking in the top 10 in the 2025 report, League City and Pearland now both rank outside the national top 10 for 2026. League City slipped from No. 6 to No. 13 this year, while Pearland dropped from No. 3 nationwide to No. 16.

These three Houston suburbs also boast highly desirable job markets for potential newcomers or current residents that want to start or change their career.

Houston proper, however, remains outside of the top 250 and is the 327th best place to live in the U.S., and it's the 60th best place to live in Texas.

Other cities in the greater Houston area that ranked among the top 100 include:

  • No. 28 – The Woodlands
  • No. 38 – Katy
  • No. 61 – Missouri City
  • No. 82 – Spring

The Lone Star State had a "strong showing" in the overall top 10 thanks to its "high affordability scores," a release said. Besides Sugar Land, three more popular Texas suburbs made the cut: Leander (No. 8) outside Austin and Dallas-Fort Worth suburbs Flower Mound (No. 3) and Frisco (No. 9).

"As prices of everyday goods continue to rise, consumers are considering affordability as a top priority when choosing a place to live," said U.S. News consumer lending analyst Erika Giovanetti. "While U.S. News’ consumer survey indicated that quality of life and affordability were close in importance, cost-of-living concerns resulted in many Americans putting what they can afford above their aspirations."

---

This article originally appeared on CultureMap.com.